Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C BURNETT

Showing results (781-790 of 921) with videos related to

Pageof 93
Sort By:
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.
Journal of Structural Biology|May 24, 2005
An all-atom model of the pore-like structure of hexameric VP40 from Ebola: structural insights into the monomer-hexamer transitionTam Luong Nguyen, Guy Schoehn, Winfried Weissenhorn, et al.
International Journal of Cardiology|August 18, 2014
The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failureValentina Cannone, Simona Barlera, Silvana Pileggi, et al.
Plos One|December 19, 2017
A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA)Valentina Cannone, Christopher G Scott, Paul A Decker, et al.
Circulation Research|April 2, 2019
CRRL269Yang Chen, Gail J Harty, Ye Zheng, et al.
Journal of the American College of Cardiology|July 11, 1992
Remodeling and reparation of the cardiovascular systemK T Weber, P Anversa, P W Armstrong, et al.
Circulation|September 1, 1996
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II InvestigatorsC Bode, R W Smalling, G Berg, et al.
The New England Journal of Medicine|September 23, 1993
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocationsM J Thirman, H J Gill, R C Burnett, et al.
Journal of the American Heart Association|December 17, 2013
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionStephen J Greene, Mihai Gheorghiade, Barry A Borlaug, et al.
Frontiers in Pharmacology|February 23, 2026
Evaluation of <i>Andrographis paniculata</i> in a mouse model of influenza A viral infection using oral administration and a translationally relevant doseKashif Shamim, Grace C Burnett, Jin Zhang, et al.
Pageof 93

Showing results (781-790 of 921) with videos related to

Sort By:
Pageof 93
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.
Journal of Structural Biology|May 24, 2005
An all-atom model of the pore-like structure of hexameric VP40 from Ebola: structural insights into the monomer-hexamer transitionTam Luong Nguyen, Guy Schoehn, Winfried Weissenhorn, et al.
International Journal of Cardiology|August 18, 2014
The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failureValentina Cannone, Simona Barlera, Silvana Pileggi, et al.
Plos One|December 19, 2017
A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA)Valentina Cannone, Christopher G Scott, Paul A Decker, et al.
Circulation Research|April 2, 2019
CRRL269Yang Chen, Gail J Harty, Ye Zheng, et al.
Journal of the American College of Cardiology|July 11, 1992
Remodeling and reparation of the cardiovascular systemK T Weber, P Anversa, P W Armstrong, et al.
Circulation|September 1, 1996
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II InvestigatorsC Bode, R W Smalling, G Berg, et al.
The New England Journal of Medicine|September 23, 1993
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocationsM J Thirman, H J Gill, R C Burnett, et al.
Journal of the American Heart Association|December 17, 2013
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fractionStephen J Greene, Mihai Gheorghiade, Barry A Borlaug, et al.
Frontiers in Pharmacology|February 23, 2026
Evaluation of <i>Andrographis paniculata</i> in a mouse model of influenza A viral infection using oral administration and a translationally relevant doseKashif Shamim, Grace C Burnett, Jin Zhang, et al.
Pageof 93